We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127)...